Table 4.
Survival data in 76 esophageal cancer patients (time in months).
| Surgery | 95% CI † | ‡ CRT + Surgery | 95% CI | p | |
|---|---|---|---|---|---|
| No. of patients | 45 | 31 | |||
| Overall survival (median) | 11.1 | 7.63 - 14.53 | 31.4 | 11.90-50.98 | 0.042 |
| Disease-specific survival (median) | 11.1 | 7.63 - 14.53 | 34.4 | 6.88-61.91 | 0.019 |
| Progression free survival (median) | 9.5 | 7.36 - 11.63 | 18.0 | 8.48 - 27.52 | 0.064 |
| DMFS ¶ (median) | 9.6 | 6.75 - 12.50 | 17.94 | 6.39 - 29.48 | 0.058 |
| # LR free survival (median) | X | X | 0.67 | ||
| Patients free of LR after 3 years | 69% | 71% | |||
| Patients free of LR after 5 years | 61% | 71% | |||
| 1 year overall survival rate | 44% | 68% | |||
| 3 year overall survival rate | 24% | 44% | |||
| 5 year overall survival rate | 16% | 29% |
† Confidence interval. ‡ Chemoradiotherapy. ¶ Distant metastasis free survival. # Local recurrence. X = not reached. Local recurrence free survival stands for survival from treatment start until disease recurrence in the field of radiotherapy and/or field of surgery in the mediastinum.